Changes in weight, body composition and metabolic parameters after switch to either dolutegravir/lamivudine or doravirine/tenofovir/lamivudine compared to continued treatment with dolutegravir/tenofovir/lamivudine for virologically suppressed HIV infection: A randomized open-label superiority trial. The AVERTAS-2 trial.

Department of Infectious Diseases, Hvidovre Hospital0 个研究点目标入组 126 人开始时间: 2020年2月14日最近更新: 2020年7月13日

试验速览

暂无简介。

•- Individuals >18 years
•- Diagnosed HIV
•- At least 6 months of ongoing treatment with dolutegravir/ tenofovirdisproxil/lamivudin prior to inclusion
•- Plasma viral load (HIV-RNA) < 50 copies/ml
•- Women of reproductive potential will be included if using approved contraception.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 126
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Pre-existing viral resistance mutations to lamivudine, dolutegravir, tenofovir or doravirine
•- History of or positive hepatitis B antigen (HBsAg) test
•- Cancer within the 5 past years
•- Pregnancy or breastfeeding
•- Any case of diabetes or cardiovascular disease must be stable assessed by the treating physician

发起方

Department of Infectious Diseases, Hvidovre Hospital